Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News

Pharma News

Amgen Provides Update On Status Of Parsabiv™ (Etelcalcetide) New Drug Application (NDA) Submitted To The U.S. Food And Drug Administration (FDA)
Amgen Provides Update On Status Of Parsabiv™ (Etelcalcetide) New Drug Application (NDA) Submitted To The U.S. Food And Drug Administration (FDA)
THOUSAND OAKS, CA, USA I August 24, 2016 I Amgen (Nasdaq.
Pharmaceutical company brings more investment to Greenville
Pharmaceutical company brings more investment to Greenville
A pharmaceutical development and manufacturing company announced Wednesday it is renovating an existing building to triple the capacity of its stability storage space.
Sleep hormone may suppress breast cancer growth
Sleep hormone may suppress breast cancer growth
Suggesting a link between lack of sleep and increased risk of breast cancer, a new study has found that melatonin, a hormone produced in the human brain at night to regulate sleep cycles, appears to s...
Chinese scientists discover molecules to repair organs
Chinese scientists discover molecules to repair organs
XIAMEN, Aug.
U.K. finds big issues with Pfizer Hospira plant in India
U.K. finds big issues with Pfizer Hospira plant in India
Pfizer was well aware that a Hospira plant in India had a history of issues when it acquired the sterile injectable drug maker last year for $15 billion.
Pfizer to Buy Antibiotics From AstraZeneca for $725 Million
Pfizer to Buy Antibiotics From AstraZeneca for $725 Million
Pfizer Inc.
Major need for safer antiarrhythmic drugs will continue to plague atrial fibrillation market, says GlobalData
Major need for safer antiarrhythmic drugs will continue to plague atrial fibrillation market, says GlobalData
While the overall level of unmet need in the atrial fibrillation market is generally considered moderate, the need for safer antiarrhythmic drugs for the maintenance of sinus rhythm is still a major i...
Senators press Mylan Labs over ‘outrageous’ EpiPen pricing
Senators press Mylan Labs over ‘outrageous’ EpiPen pricing
Move over, Martin Shkreli.
NICE knocks Bayer's Nexavar as CDF review continues
NICE knocks Bayer's Nexavar as CDF review continues
Add Bayer to the list of drugmakers that are feeling the heat from NICE’s Cancer Drugs Fund takeover.
Pfizer to Buy Cancer Drug Maker in $14 Billion Deal
Pfizer to Buy Cancer Drug Maker in $14 Billion Deal
Medivation, which makes the big-selling drug Xtandi to treat prostate cancer, has finally found its buyer in a fellow American drug maker, Pfizer.
AstraZeneca and Lilly receive FDA Fast Track designation for AZD3293, an investigational treatment for early Alzheimer’s disease
AstraZeneca and Lilly receive FDA Fast Track designation for AZD3293, an investigational treatment for early Alzheimer’s disease
AstraZeneca and Eli Lilly and Company (Lilly) have received US Food and Drug Administration (FDA) Fast Track designation for the development programme in Alzheimer’s disease for AZD3...
FDA Approves TROXYCA® ER (oxycodone hydrochloride and naltrexone hydrochloride) Extended-Release Capsules CII with Abuse-Deterrent Properties for the Management of Pain
FDA Approves TROXYCA® ER (oxycodone hydrochloride and naltrexone hydrochloride) Extended-Release Capsules CII with Abuse-Deterrent Properties for the Management of Pain
NEW YORK--(BUSINESS WIRE) -- Pfizer Inc.
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand